The FDA granted breakthrough therapy designation to elranatamab for treatment of relapsed or refractory multiple myeloma.
Elranatamab (Pfizer) is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody. The agent is designed to bind to BCMA — which is highly expressed on the surface of multiple myeloma cells — and the CD3 receptor found on the surface of T cells.
“The FDA’s breakthrough designation recognizes the potential of elranatamab as an innovative medicine for people with multiple myeloma whose disease has relapsed or is refractory to existing
